CHReporter · Apr 2026
Profile piece describing Bramante as a young but notable American biomanufacturing startup focused on modular GMP/manufacturing infrastructure and robotics-first operations.
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Bramante Biologics Corporation (Bramante) is a Cambridge-based, YC-backed life-sciences manufacturing startup building AI/API-first lab instruments and recombinant reagents, with an onshore CDMO angle for protein therapeutics and modular microfactories. Public materials emphasize domestic manufacturing in Massachusetts, direct engineer access, and design-partner-led deployment; no separate CEO was publicly identified in the sources reviewed.
Primary product
AI/API-first life-sciences instruments and recombinant reagents for automated/robotic labs; adjacent modular biomanufacturing microfactories for protein therapeutics.
Founded
2024
Headquarters
Cambridge, Massachusetts, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Biomanufacturing CDMO / life-sciences instruments and reagents
Offices
160 Alewife Brook Parkway, #1316, Cambridge, MA 02138, United States
Business model
B2B hardware sales
reagent sales
contract manufacturing / CDMO services
service and support contracts
design-partner program
Funding
Stage
Seed
Total raised
$500K
Latest round
Seed · Jun 2025
Latest amount
$500K
Jun 2025
People & investors
Work & culture
Engineering-first, founder-accessible, and design-partner-driven culture centered on domestic manufacturing, rapid iteration, and tight feedback loops with labs and CDMO users.
Compensation
No public compensation bands or salary data were found.
Benefits
Direct access to engineering
Monthly cohort roundtable
Closed-loop QC
Pre-production alpha/beta units
Preferred founding-cohort pricing
Same-week parts
Annual on-site support included
Product & market
Pricing
Public catalog pricing plus direct sales/service agreements; custom commercial terms for instruments, reagents, and design-partner programs.
Differentiators
- —Made and tested in Massachusetts
- —Real REST API, Python SDK, and MCP server in the box
- —Direct line to the engineer who built the unit
- —Modular containerized microfactories
- —Domestic supply-chain positioning
- —Annual on-site service included
Technology
REST API
Python SDK
MCP server
Claude Code integration
AI-driven monitoring
closed-loop QC
modular container-based microfactories
robotics integration
Customers
pharmaceutical companies
drug developers
CDMOs
research institutions
healthcare providers
Scale & contact
Estimated revenue
≈$220K ARR (estimated, Sep 2025)
Latest news
Startup Intros · Jun 2025
Startup Intros reports Bramante Biologics raised a $500K Seed round on June 1, 2025, with Y Combinator and Christian Vollmann among the identified investors.
Y Combinator · May 2025
YC launch describing Bramante as building American drug manufacturing capacity with microfactories, AI-designed therapeutics support, and domestic supply-chain goals.
LinkedIn · May 2025
Scott Stankey publicly announced Bramante Biologics, describing the company’s mission to strengthen American biomanufacturing and make advanced-drug manufacturing faster and more scalable.
Fondo
Launch coverage reiterating the company’s U.S.-based biomanufacturing mission, modular microfactory approach, and founder background from Protein Evolution.
Jobs and careers at Bramante Biologics
0 jobs at Bramante Biologics
No open positions
Check back later for new openings